1 Table of Contents

1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 5

2 Introduction 6
2.1 Bone Cement Overview 6

3 Products under Development 7
3.1 Bone Cement - Pipeline Products by Stage of Development 7
3.2 Bone Cement - Pipeline Products by Segment 8
3.3 Bone Cement - Pipeline Products by Territory 9
3.4 Bone Cement - Pipeline Products by Regulatory Path 10
3.5 Bone Cement - Pipeline Products by Estimated Approval Date 11

4 Bone Cement - Pipeline Products under Development by Companies 12
4.1 Bone Cement Companies - Pipeline Products by Stage of Development 12
4.2 Bone Cement - Pipeline Products by Stage of Development 13

5 Bone Cement Companies and Product Overview 14
5.1 aap Implantate AG Company Overview 14
5.1.1 aap Implantate AG Pipeline Products & Ongoing Clinical Trials Overview 14
5.2 Biofix Medical Technologies Company Overview 17
5.2.1 Biofix Medical Technologies Pipeline Products & Ongoing Clinical Trials Overview 17
5.3 Bone-Rad Therapeutics, Inc. Company Overview 18
5.3.1 Bone-Rad Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 18
5.4 Exactech, Inc. Company Overview 19
5.4.1 Exactech, Inc. Pipeline Products & Ongoing Clinical Trials Overview 19
5.5 Graftys SAS Company Overview 21
5.5.1 Graftys SAS Pipeline Products & Ongoing Clinical Trials Overview 21
5.6 Meta Biomed Co., Ltd. Company Overview 22
5.6.1 Meta Biomed Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 22
5.7 Onbone Oy Company Overview 24
5.7.1 Onbone Oy Pipeline Products & Ongoing Clinical Trials Overview 24
5.8 Orthox Ltd. Company Overview 25
5.8.1 Orthox Ltd. Pipeline Products & Ongoing Clinical Trials Overview 25
5.9 Osseon Therapeutics, Inc. Company Overview 26
5.9.1 Osseon Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 26
5.10 Ozics AG Company Overview 27
5.10.1 Ozics AG Pipeline Products & Ongoing Clinical Trials Overview 27
5.11 Queen’s University Belfast Company Overview 29
5.11.1 Queen’s University Belfast Pipeline Products & Ongoing Clinical Trials Overview 29
5.12 Sree Chitra Tirul Institute for Medical Sciences & Technology Company Overview 30
5.12.1 Sree Chitra Tirul Institute for Medical Sciences & Technology Pipeline Products & Ongoing Clinical Trials Overview 30
5.13 Synthes, Inc. Company Overview 31
5.13.1 Synthes, Inc. Pipeline Products & Ongoing Clinical Trials Overview 31
5.14 Teknimed S.A. Company Overview 32
5.14.1 Teknimed S.A. Pipeline Products & Ongoing Clinical Trials Overview 32
5.15 University of Limerick Company Overview 35
5.15.1 University of Limerick Pipeline Products & Ongoing Clinical Trials Overview 35
5.16 Zimmer Biomet Holdings, Inc. Company Overview 38
5.16.1 Zimmer Biomet Holdings, Inc. Pipeline Products & Ongoing Clinical Trials Overview 38

6 Bone Cement- Recent Developments 40
6.1 Apr 20, 2016: Stryker reports first quarter 2016 results 40
6.2 Mar 03, 2016: Stryker Raises USD750 Million in Public Offering of 2% Notes Due 2019 41
6.3 Mar 03, 2016: Stryker Raises USD1 Billion in Public Offering of 4.625% Notes Due 2046 41
6.4 Mar 03, 2016: Stryker Raises USD1 Billion in Public Offering of 3.5% Notes Due 2026 41
6.5 Mar 03, 2016: Stryker Raises USD750 Million in Public Offering of 2.625% Notes Due 2021 42
6.6 Jan 28, 2016: Vexim Raises USD11.3 Million in Private Placement of Shares 42
6.7 Jan 26, 2016: Stryker Reports 2015 Results and 2016 Outlook 42
6.8 Jan 26, 2016: Stryker Announces the Retirement of William R. Jellison and the promotion of Glenn S. Boehnlein to Vice President, Chief Fincial Officer 43
6.9 Jan 12, 2016: Stryker Provides 2015 Prelimiry Sales Results and Increases Adjusted Earnings Guidance 44
6.10 Oct 22, 2015: Stryker Reports Third Quarter 2015 Results 45
6.11 Oct 19, 2015: U.S. Supreme Court To Hear Stryker’s Appeal In Zimmer Patent Infringement Suit 46
6.12 Oct 14, 2015: Ziehm Imaging and Stryker Partner to Provide Surgical vigation with Ziehm Vision RFD 3D 46
6.13 Jul 23, 2015: Stryker Reports Second Quarter 2015 Results 47

7 Appendix 48
7.1 Methodology 48
7.2 About GlobalData 50
7.3 Contact Us 51
7.4 Disclaimer 51